Mesothelioma other diagnostic studies
|
Mesothelioma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Mesothelioma other diagnostic studies On the Web |
|
American Roentgen Ray Society Images of Mesothelioma other diagnostic studies |
|
Risk calculators and risk factors for Mesothelioma other diagnostic studies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sujit Routray, M.D. [2]
Overview
- Antibodies to cytokeratin proteins are positive, differentiating these neoplasms from many sarcomas but not adenocarcinomas.
- The absence of staining with CEA or Leu-M1 differentiates them from adenocarcinomas.
- Recent evidence shows that Wilms’ Tumor Antigen 1 may help differentiate mesothelioma from adenocarcinoma.
Other Diagnostic Studies
Position Emission Tomography
- Positron emission tomography is becoming useful in two clinical settings:[1]
- Differentiating between benign and malignant asbestos-related pleural thickening
- Assessing for nodal metastases
- In addition, there appears to be a correlation between the degree of FDG uptake and the biological aggressiveness of the tumor, which may help to guide treatment.[1]
Fluorescence In Situ Hybridization (FISH)
- FISH may be helpful in the diagnosis of mesothelioma. It helps in distinguishing malignant mesothelioma from reactive mesothelial cells in effusions.[2]
- Mutlitarget FISH assay may be used to detect chromosomal abberations (chromosomes 3, 7, chromosome 17|17]], and 9p21).[2]
- M
References
- ↑ 1.0 1.1 Radiographic findings of mesothelioma. Dr Bruno Di Muzio and A.Prof Frank Gaillard et al. Radiopaedia 2016. http://radiopaedia.org/articles/mesothelioma. Accessed on February 8, 2015
- ↑ 2.0 2.1 Savic S, Franco N, Grilli B, Barascud Ade V, Herzog M, Bode B; et al. (2010). "Fluorescence in situ hybridization in the definitive diagnosis of malignant mesothelioma in effusion cytology". Chest. 138 (1): 137–44. doi:10.1378/chest.09-1951. PMID 20139227.